Parvathy P, Lekha G S, Aparna S, Kanagarajan A
Research Associate, Siddha Regional Research Institute, Thiruvananthapuram, India.
Research Associate, Siddha Regional Research Institute, Thiruvananthapuram, India.
J Ayurveda Integr Med. 2024 Nov-Dec;15(6):100993. doi: 10.1016/j.jaim.2024.100993. Epub 2024 Dec 2.
Diabetic Nephropathy is one of the major microvascular complications of Diabetes Mellitus, which can be detected in the earlier stage by investigating urinary microalbumin excretion levels and estimating ACR and GFR. Early treatment can delay or prevent the progression of diabetic Nephropathy. Monoherbal Siddha formulation Sirupeelai Kudineer indicated for the complications of Diabetes Mellitus is selected for this Case study. The efficiency of the drug was assessed by measuring the change in renal function throughout the treatment period and the KD QOL assessment. Four patients presented with symptoms of Diabetic Nephropathy were treated with the monoherbal Siddha formulation Sirupeelai Kudineer. This series of four cases showed improvement in CKD QOL and some biochemical parameters. Blood urea was reduced in the four cases during medication. Serum creatinine levels mildly increased in three cases somewhere during the treatment period but decreased in all four cases after treatment. The estimated GFR also improved in three cases after treatment but mildly reduced in one patient. Symptomatic improvement was also observed in all the patients. Marked reduction in blood urea and serum creatinine levels after treatment shows the Nephroprotective action of the drug. The clinical and laboratory parameters observed among these four patients suggest that this drug may be used along with other hypoglycemic drugs to treat Diabetic Nephropathy.
糖尿病肾病是糖尿病的主要微血管并发症之一，可通过检测尿微量白蛋白排泄水平以及估算尿白蛋白肌酐比值（ACR）和肾小球滤过率（GFR）在早期阶段进行检测。早期治疗可延缓或预防糖尿病肾病的进展。本病例研究选用了用于治疗糖尿病并发症的单味 Siddha 制剂 Sirupeelai Kudineer。通过在整个治疗期间测量肾功能变化以及进行肾脏疾病生活质量（KD QOL）评估来评估该药物的疗效。对四名出现糖尿病肾病症状的患者使用单味 Siddha 制剂 Sirupeelai Kudineer 进行治疗。这一系列的四个病例显示出慢性肾脏病生活质量（CKD QOL）和一些生化参数有所改善。用药期间，四名患者的血尿素均有所降低。在治疗期间，三名患者的血清肌酐水平在某个阶段略有升高，但治疗后所有四名患者的血清肌酐水平均下降。三名患者治疗后的估算肾小球滤过率也有所改善，但有一名患者略有降低。所有患者均观察到症状改善。治疗后血尿素和血清肌酐水平显著降低表明该药物具有肾脏保护作用。这四名患者中观察到的临床和实验室参数表明，该药物可与其他降糖药物联合使用来治疗糖尿病肾病。
